Skip to main content

Advertisement

Table 1 Characteristics of patients with GT3-HCV infection who received a sofosbuvir containing treatment regime

From: Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

  Total SOF + DCV SOF + DCV + RBV SOF+ VEL
Sample size 102 57 24 21
Age 39.99 (38.22–41.76) 39.16 (36.83–41.48) 44.25 (40.8–47.70) 37.38 (33.10–41.67)
Gender (M/F) 62/40 28/29 20/4 13/8
Route of Infection (Travenous drug abuse/Blood products/Others) 58/18/26 34/7/16 10/6/8 14/5/2
Cirrhosis(yes/no) 33/69 4/53 24/0 5/16
Baseline HCV RNA (log10 IU/ml) 6.23 (6.04–6.43) 6.26 (5.99–6.54) 6.33 (5.94–6.73) 6.04 (5.60–6.48)
Baseline ALT (IU/mL) 95.70 (78.88–112.51) 102.67 (78.10–127.24) 112.68 (78.89–146.47) 57.37 (30.01–84.72)
Baseline AST (IU/mL) 81.96 (72.12–91.80) 91.33 (77.48–105.19) 89.86 (71.20–108.52) 47.50 (31.63–63.36)
Baseline TBil (μmol/mL) 19.95 (18.57–21.32) 18.91 (17.22–20.59) 22.01 (18.07–25.94) 20.42 (18.07–22.77)
Baseline PLT (109/L) 142.94 (129.36–156.52) 157.65 (139.05–176.25) 104.96 (79.71–130.21) 146.43 (117.94–174.91)
Baseline FIB-4 4.03 (2.99–5.07) 3.75 (2.27–5.23) 5.70 (3.81–7.58) 2.86 (0.52–5.19)
Baseline APRI 2.15 (1.66–2.64) 2.07 (1.40–2.74) 3.11 (2.02–4.20) 1.26 (0.36–2.16)